GSK208467 (Sarcoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the study drug (GSK3377794) can help people with synovial sarcoma or with myxoid/round cell liposarcoma.

We also want to learn more about how safe and effective the study drug is

Who Can Participate in the Study?

Adults with advanced synovial sarcoma, or myxoid/round cell liposarcoma.

For more information on who can participate in this study please contact the study team.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Give blood samples and a sample of your tumor tissue to find out if you can participate
-Have a procedure called leukapheresis, which filters your blood through a machine and removes
some of your white blood cells (lasts about 4 hours). Your white blood cells will be used to make the study drug
-Get chemotherapy with fludarabine and cyclophosphamide for 3-4 days into a vein
-Have a hospital admission to get the Study drug (GSK3377794)
-Complete follow-up phone calls and visits

Study Details

Full Title
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO). Substudy 1- Evaluation of Safety and Antitumor Activity of GSK3377794 in HLAA2+ Participants with NY-ESO-1 Positive Previously Untreated Advanced Metastatic or Unresectable Synovial Sarcoma. Substudy 2 - Evaluation of Safety and Antitumor Activity of GSK3377794 in HLAA2+ Participants with NY-ESO-1 Positive Previously Treated Advanced Metastatic or Unresectable Synovial Sarcoma.
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00103440
NCT: NCT03967223
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698